Societal CDMO (SCTL) Stock Price
Societal CDMO Price
Revenue has compounded at 7.8% per year over the past 8 years to 94.64 M USD. Societal CDMO's net margin stands at -14.0%, up from -38.7% several years earlier.
Societal CDMO stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Societal CDMO business model & stock analysis
Frequently asked questions about Societal CDMO
Recro Pharma Inc operates as a specialty pharmaceutical company. Its business model involves developing and commercializing innovative products for hospital and ambulatory care settings. Recro Pharma focuses on therapies that address pain management, acute care, and other medical needs. By leveraging its expertise in formulation and manufacturing, the company aims to provide advanced solutions to healthcare professionals and patients. With a commitment to delivering high-quality pharmaceuticals, Recro Pharma Inc continues to contribute to the improvement of patient outcomes and enhance medical treatment options.
Recro Pharma Inc is primarily active in the pharmaceutical industry.
The main competitors of Recro Pharma Inc in the market include companies such as Mallinckrodt Pharmaceuticals, Pfizer Inc, and Amneal Pharmaceuticals.
Recro Pharma Inc is a pharmaceutical company with a rich history and background. Established in 2007, the company is based in Malvern, Pennsylvania. Recro Pharma specializes in developing and commercializing innovative therapies for acute care settings. They focus on creating non-opioid pain management solutions, addressing the growing need for safer and more effective alternatives. The company's dedicated team of scientists and researchers work diligently to provide patients with advanced pharmaceutical products. Recro Pharma's commitment to excellence and dedication to improving patient outcomes has earned them a reputable position in the pharmaceutical industry.
Recro Pharma Inc has achieved several significant milestones. The company successfully developed and gained FDA approval for its lead product, IV meloxicam, a non-opioid pain management option. They also secured a licensing agreement for IV meloxicam with Baudax Bio Inc and expanded its use to multiple surgical indications. In addition, Recro Pharma Inc successfully completed a Phase III clinical trial for a new treatment option targeting postoperative pain. The company continues to focus on research and development to provide innovative solutions for patients and healthcare professionals. Recro Pharma Inc's achievements highlight their commitment to advancing pain management and improving patient outcomes.
Recro Pharma Inc primarily operates in the United States.
Recro Pharma Inc represents values of innovation, integrity, and patient-centricity. As a pharmaceutical company, Recro Pharma is dedicated to developing and delivering high-quality medications to patients in need. The company's corporate philosophy emphasizes delivering innovative drug solutions that meet the highest standards of safety and efficacy. Recro Pharma is committed to conducting business ethically and maintaining strong relationships with healthcare professionals, patients, and stakeholders. Through its dedication to research and development, Recro Pharma aims to improve patient outcomes and enhance the quality of life for individuals around the world.
10 analysts currently rate the Societal CDMO stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Societal CDMO to generate revenue of 123.71 M USD and earnings per share of 0.06 USD.
The Societal CDMO share (SCTL) is listed on 2 stock exchanges, including: NASDAQ (REPH), Frankfurt (RAH.F).
Recro Pharma Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative drugs to improve the health and well-being of patients worldwide. The company has three main divisions: Acute Care, Contract Development and Manufacturing Organization (CDMO), and Healthcare. Within the Acute Care division, the company has a portfolio of pain treatment drugs, including intravenous (IV) acetaminophen injections, methoxyflurane inhalers, and sublingual sufentanil tablets. The CDMO division offers manufacturing services for customers in the biotechnology and pharmaceutical industries. These services include process development and optimization, clinical and commercial manufacturing, stability studies, and quality assurance services. Recro Pharma's Healthcare division focuses on developing products to enhance patient care and safety. For example, the company is currently developing a novel nasal spray for the treatment of severe opioid overdoses. Recro Pharma relies on collaboration with partners and acquisitions of companies that complement its capabilities and processes necessary to create new solutions in the pharmaceutical products and services field. For example, the company was acquired by Alkermes plc in 2015 to acquire specialized formulation expertise and production capacity to complement its own resources. Recro Pharma's business model is based on focusing on continuous improvement of treatment options and patient care through innovative and effective drugs and services that are at the forefront of technology. The company intends to expand its drug development platform through technology partnerships, licensing of intellectual property, and acquisitions of companies to bring future products to market faster and more effectively. Overall, Recro Pharma has become a significant player in the pharmaceutical industry, catering to the needs of physicians, patients, and OEMs worldwide. Recro Pharma offers a wide range of innovative drugs and services that contribute to better healthcare and higher patient satisfaction.
The expected revenue of Societal CDMO is 123.71 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Societal CDMO is 5.71 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Societal CDMO at the moment.
The P/S cannot be calculated for Societal CDMO currently.
The Eulerpool Quality Score for Societal CDMO is 2/10.
The ISIN of Societal CDMO is US75629F1093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Societal CDMO is A1XFAV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Societal CDMO is SCTL. The ticker symbol is used to trade Societal CDMO shares on the stock exchange.
Societal CDMO stock
Societal CDMO Peer Group
Societal CDMO Ticker
Societal CDMO FIGI
All fundamentals and in-depth analysis of Societal CDMO
Our stock analysis for Societal CDMO stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Societal CDMO. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.